Claims

1. A vesicular formulation, for use in the treatment of rosacea, comprising one or more phospho or sulpholipids and one or more surfactants.

2. A vesicular formulation, for use in the treatment of erythema associated with rosacea, comprising one or more phospho or sulpholipids and one or more surfactants.

3. A vesicular formulation, for use in the treatment of thread veins associated with rosacea, comprising one or more phospho or sulpholipids and one or more surfactants.

4. A vesicular formulation, for use as claimed in claim 1, claim 2 or claim 3, wherein the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

5. A vesicular formulation, for use as claimed in any one of claims 1 to 4 wherein the (molar) ratio of phospho or sulpholipid to surfactant is about 1:3 to about 30:1.

6. A vesicular formulation, for use as claimed in claim 5, wherein the (molar) ratio of phospho or sulpholipid to surfactant is about 2:1 to about 20:1.

7. A vesicular formulation, for use as claimed in any one of claims 1 to 6, wherein the formulation contains 0.2 to 10% by weight surfactant.

8. A vesicular formulation, for use as claimed in any one of claims 1 to 7, wherein the phospho or sulpholipid is phosphatidylcholine.

9. A vesicular formulation, for use as claimed in any one of claims 1 to 8, wherein the surfactant is selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. A vesicular formulation for use as claimed in any one of claims 1 to 9, wherein the surfactant is polysorbate 80 (Tween 80).

11. A vesicular formulation, for use as claimed in any one of claims 1 to 10, wherein the formulation comprises a total combination of phospho or sulpholipid and surfactant of between 6% and 14% by weight.

12. A vesicular formulation for use as claimed in any one of claims 1 to 11, wherein the formulation comprises at least 20% by weight water.

13. A method of treating rosacea, the method comprising administering a formulation, as set out in any one of claims 1 to 12.

14. Use of one or more phospho or sulpholipids and one or more surfactants in the manufacture of a medicament for the treatment of rosacea.

CLAIMS

1. A vesicular formulation for use in the treatment of rosacea, comprising one or more phospho or sulpholipids and one or more surfactants, in the absence of any pharmaceutically active agent.

2. Use of a vesicular formulation comprising one or more phospho or sulpholipids and one or more surfactants, in the absence of any pharmaceutically active agent, in the manufacture of a medicament for use in the treatment of erythema associated with rosacea.

3. Use of a vesicular formulation comprising one or more phospho or sulpholipids and one or more surfactants in the manufacture of a medicament for the treatment of thread veins associated with rosacea.

4. A vesicular formulation according to Claim 1 for a use as specified therein or a use according to Claim 2 or 3, in which the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

5. A vesicular formulation or use according to any of Claims 1 to 4, in which the molar ratio of phospho or sulpholipid to surfactant is about 1:3 to about 30:1.

6. A vesicular formulation or use according to Claim 5, in which the molar ratio of phospho or sulpholipid to surfactant is about 2:1 to about 20:1.

7. A vesicular formulation or use according to any preceding claim, in which the formulation contains 0.2 to 10% by weight surfactant.

8. A vesicular formulation or use according to any preceding claim, in which the phospho or sulpholipid is phosphatidylcholine.

9. A vesicular formulation or use according to any preceding claim, in which the surfactant is selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. A vesicular formulation or use according to any preceding claim, in which the surfactant is polysorbate 80 (Tween 80).

11. A vesicular formulation or use according to any preceding claim, in which the formulation comprises a total combination of phospho or sulpholipid and surfactant of between 6% and 14% by weight.

12. A vesicular formulation or use according to any preceding claim, in which the formulation comprises at least 20% by weight water.

13. Use of one or more phosphor or sulpholipids and one or more surfactants in the manufacture of a medicament for the treatment of rosacea.